AUROPHARMA.NS Balance Sheet
Aurobindo Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹79.95 Bn | ₹115.46 Bn | ₹121.89 Bn | ₹143.30 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹44.96 Bn | ₹27.39 Bn | ₹32.66 Bn | ₹30.09 Bn | CapitalWorkInProgress |
| Goodwill | ₹5.96 Bn | ₹5.95 Bn | ₹6.18 Bn | ₹8.00 Bn | Goodwill |
| Other Intangible Assets | ₹24.32 Bn | ₹23.52 Bn | ₹19.87 Bn | ₹22.77 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹3.02 Bn | ₹2.27 Bn | ₹2.06 Bn | ₹1.95 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹7.05 Bn | ₹6.13 Bn | ₹7.31 Bn | ₹8.28 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹183.44 Bn | ₹208.66 Bn | ₹226.23 Bn | ₹257.93 Bn | NoncurrentAssets |
| Inventories | ₹85.11 Bn | ₹98.08 Bn | ₹105.44 Bn | ₹120.53 Bn | Inventories |
| Trade Receivables | ₹44.66 Bn | ₹48.17 Bn | ₹57.46 Bn | ₹70.94 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹43.96 Bn | ₹33.93 Bn | ₹55.69 Bn | ₹71.91 Bn | CashAndCashEquivalents |
| Current Investments | ₹1.51 Bn | ₹0.51 Bn | ₹0.00 Bn | ₹7.47 Bn | CurrentInvestments |
| Other Current Assets | ₹19.54 Bn | ₹25.36 Bn | ₹23.57 Bn | ₹28.03 Bn | OtherCurrentAssets |
| Total Current Assets | ₹215.46 Bn | ₹237.72 Bn | ₹271.62 Bn | ₹327.09 Bn | CurrentAssets |
| Total Assets | ₹398.90 Bn | ₹450.72 Bn | ₹497.85 Bn | ₹585.02 Bn | Assets |
| Equity Share Capital | ₹0.59 Bn | ₹0.59 Bn | ₹0.58 Bn | ₹0.58 Bn | EquityShareCapital |
| Other Equity | ₹267.81 Bn | ₹297.84 Bn | ₹325.95 Bn | ₹378.33 Bn | OtherEquity |
| Equity Attributable to Owners | ₹268.40 Bn | ₹298.43 Bn | ₹326.53 Bn | ₹378.91 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹0.12 Bn | ₹0.08 Bn | ₹-0.06 Bn | ₹-0.08 Bn | NonControllingInterest |
| Total Equity | ₹268.52 Bn | ₹298.51 Bn | ₹326.47 Bn | ₹378.83 Bn | Equity |
| Long-term Borrowings | ₹6.19 Bn | ₹21.35 Bn | ₹15.62 Bn | ₹8.03 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹15.44 Bn | ₹30.22 Bn | ₹24.56 Bn | ₹25.80 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹42.43 Bn | ₹41.80 Bn | ₹63.80 Bn | ₹68.73 Bn | BorrowingsCurrent |
| Trade Payables | ₹38.71 Bn | ₹44.54 Bn | ₹41.89 Bn | ₹55.67 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹11.43 Bn | ₹8.77 Bn | ₹5.47 Bn | ₹6.26 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹114.94 Bn | ₹121.99 Bn | ₹146.82 Bn | ₹180.39 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹398.90 Bn | ₹450.72 Bn | ₹497.85 Bn | ₹585.02 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from AUROPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).